Domainex newsletter

All the latest news and industry insights from the Domainex team

Hayley French, CEO

A Message from Hayley French, New CEO of Domainex

I’m Hayley French and I’m delighted to introduce myself as the new Chief Executive Officer of Domainex. I have over two decades of experience in the life sciences sector working in senior commercial roles and as an attorney in pharmaceutical and biotechnology organisations. I look forward to applying my experience in strategic development, business operations, and commercialisation to continue building strong partnerships across the industry and lead Domainex through its next stage of growth.

Domainex has a strong reputation for innovation and delivery in drug discovery and I am excited to join such a talented team. We will continue to work closely with our partners and clients to build on that foundation and drive growth and success. If we've not yet met, I look forward to seeing you over the coming months.

Covalent Drug Discovery: Challenges, Advances and Success Stories

Check out Dr Andrew Ratcliffe and Dr Scott Martin's recent article in International Pharmaceutical Industry on the rise and challenges of covalent drug discovery

Advancements in Hit Identification for Membrane Protein Drug Discovery

In this article for Drug Target Review, Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa (polymer nanodiscs) are helping to overcome hurdles in membrane protein drug discovery, with a focus on the Adenosine A2a receptor.

Domainex Supports Sitryx's MTHFD2 Programme

Domainex is delighted to have supported Sitryx’s MTHFD2 programme which resulted in SIT047, a novel, oral inhibitor, progressing to clinical development for psoriatic arthritis. Over the course of the programme, Domainex provided an integrated team including assay biology, medicinal chemistry, structural biology and bioanalytical services.

Nomination for NRG5051

We are delighted that NRG Therapeutics has achieved a key milestone with the nomination of its first development candidate, NRG5051, and has secured a $5 million award from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). Domainex is proud to have supported this project by providing integrated lead optimization services including assay biology and medicinal and computational chemistry.

New recruits

Welcome to the Domainex team to Nadine Myers and Michael Carter. Visit our website to view the current available opportunities and find out more about working at Domainex.